Boston Scientific Corporation (BSX) — closed signal from August 20, 2025
Partial Published before the outcome was known, scored automatically when the window closed on November 18, 2025.
Predicted vs. what happened
What happened
Reached 28% of the predicted growth at its peak, without hitting the target.
The thesis — published August 20, 2025
BSX looks like it may rebound after a pullback, with signs the recent average price is turning up even though longer-term momentum is still sluggish. Recent news in medical devices is upbeat, as peers winning FDA approvals can lift interest in the whole group and spark dip buying. Plan to buy only on small drops with tight downside limits, and consider adding if momentum improves. This is a short-term trade idea, not a long-term revaluation.
Primary drivers
- Price looks beaten down while recent average price is edging up
- Investor mood is strong, helped by positive attention in med-tech
- New products coming and steady hospital demand help the outlook
- Wait for clearer upward momentum before adding more shares later
How it played out
BSX: target was not reached
Lyra published BSX at 104.84 on 2025-08-20 as a short-term rebound idea. The thesis expected 16% growth and pointed to a beaten-down price, a recent average price edging up, strong investor mood around med-tech, new products, and steady hospital demand. It also called for waiting on clearer upward momentum before adding more.
Inside the window, BSX rose to 109.50 on 2025-09-09, a 4.4% peak gain. That stayed below the 121.61 target. The target was never reached. By 2025-11-18, the stock ended at 99.22. The thesis only partially played out: there was an early rebound, but it faded and missed the target.
What happened during the window
On 2025-10-22, Investor's Business Daily reported that Boston Scientific posted adjusted earnings of 0.75 per share on 5.07 billion in revenue for the third quarter. The same report said Watchman sales grew 35% and electrophysiology sales grew 63%.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.